22 October 2020 in Current Urology Reports
Purpose of Review This article aims to describe the impact of the COVID-19 pandemic on American urology trainees, with a focus on virtual learning initiatives. Recent Findings Urological education was forced to rapidly adapt to the COVID-19 pandemic in 2020. Significant challenges included quarantines, redeployment of residents and faculty, and suspension of regularly scheduled conferences. In response, urologists across the country adopted web-based platforms to develop virtual lecture series to fill the gap. Popular programs for residents included UCSF’s COViD (Collaborative Online Video Didactics) series and the New York Section of the American Urological Association’s EMPIRE (Educational Multi-institutional Program for Instructing REsidents) series. Summary Virtual education programs have enabled urology trainees to pursue their education during the pandemic. While the long-term impact of the pandemic on urology training remains unknown, some good may be found in the innovative solutions that have arisen in urology education.
18 November 2022 in Clinical Genitourinary Cancer
1 January 2021 in Journal of Endourology
INTRODUCTION AND OBJECTIVES Patients with obstructive pyelonephritis (OPN) require urgent decompression via retrograde ureteral stenting (RUS) or percutaneous nephrostomy (PCN). In 2016, the urology and interventional radiology departments at our institution established a protocol for patients with OPN with sepsis. The primary objectives were to assess this protocol's impact on improving time to decompression and whether more expedient decompression decreased length of stay (LOS). Secondarily, we assessed the impact of the protocol and clinical factors on receipt of PCN over RUS. METHODS 147 patients at our institution who underwent PCN from 2012 – 2017 or stent from 2014 - 2017 for stone-related OPN meeting sepsis criteria were retrospectively reviewed. Univariate descriptive statistics compared patient characteristics and outcomes between RUS and PCN pre- and post-protocol implementation. Multivariable logistic regression assessed predictors of decompression with PCN (vs RUS) and of prolonged LOS (>5 days). RESULTS Utilization of PCN increased after implementation of the protocol from 4 PCN/yr to 14 PCN/yr with a decrease in the median time from urologic consultation to PCN from 9.2 hours to 4.3 hours (p = 0.001) with overall median time to decompression decreasing from 5.4 to 4.5 hours (p = 0.017). Predictors of undergoing PCN (vs RUS) included increasing comorbidity and ≥1cm obstructing stone. On multivariable analysis controlling for comorbidity, leukocytosis, and septic shock, increasing hours to decompression increased odds of prolonged LOS (1.08, 95%CI 1.02 - 1.15, p = 0.014). CONCLUSIONS After implementing our OPN with sepsis protocol, time to decompression decreased with dramatic improvement in time to PCN. Quicker decompression was independently associated with reduced odds of prolonged hospital stay. A well-designed protocol engages both urology and IR in the management of these acutely ill patients and improves outcomes.
1 August 2023 in Journal of Endourology
The purpose of this report is to describe a novel salvage surgical technique combining cryo-ablation of the prostate and robotic excision of the seminal vesicle for locally recurrent prostate cancer of the seminal vesicle with or without prostate involvement following radiation therapy or focal therapy. Seven men with biopsy-proven locally recurrent prostate cancer involving the seminal vesicle with or without adjacent prostate following primary radiation or focal therapy underwent combined salvage focal cryoablation and robotic excision of the seminal vesicle. Descriptive statistics characterized the cohort and outcomes. Median follow up was 1.4 years. There were no surgical complications, and length of stay was one day in all cases. No patients experienced any new urinary incontinence following removal of the catheter. Erectile function was preserved in both men exhibiting pre-operative erections adequate for intercourse. Of the 4 patients developing recurrent disease, 3 involved only the contralateral seminal vesicle; they all underwent a second salvage focal cryoablation and robotic seminal vesiculectomy. One presenting with high-risk disease developed systematic metastasis. He is alive and managed with androgen deprivation therapy. One developed persistent local disease recurrence and is on androgen deprivation therapy. The other five are disease-free based on the most recent mpMRI and PSA. This study highlights the feasibility and effectiveness of salvage focal cryoablation and robotic seminal vesiculectomy as a salvage treatment for locally recurrent prostate cancer of the seminal vesicle with or without involvement of the prostate following primary radiation or focal therapy. Based on our outcomes, we recommend considering a bilateral salvage focal cryoablation and robotic seminal vesiculectomy in men with unilateral seminal vesicle recurrence following primary radiation therapy. We recommend unilateral salvage focal cryoablation and seminal vesiculectomy in men with unilateral seminal vesicle and prostate involvement following primary partial cryo-ablation provided no contralateral disease is identified.
1 January 2026 in JCO Oncology Advances
PURPOSE: Increased heterogeneity in outcomes has been observed postnephrectomy in patients with renal cell carcinoma (RCC), with standard clinical parameters being primarily used for risk assessment. Currently, no blood-based biomarkers are available for molecular residual disease (MRD) detection in RCC. Herein, we performed a multicenter, real-world evaluation of the prognostic value of circulating tumor DNA (ctDNA) in resected RCC. METHODS: This real-world evidence-based multi-institutional study included a cohort of 77 patients with stage I-IV RCC. Longitudinal ctDNA testing was performed on plasma samples (n = 295) using a clinically validated, personalized, tumor-informed ctDNA assay (Signatera, Natera, Inc, Austin, TX). ctDNA results were analyzed, and association with recurrence-free survival was assessed. RESULTS: The patient cohort included 77 patients with stage I-IV RCC (clear cell: 64, non–clear cell: 13). Patients who tested ctDNA-positive during the MRD window experienced worse prognosis and a higher likelihood of recurrence (hazard ratios, 18; P < .0001) compared with their ctDNA-negative counterparts. CONCLUSION: Overall, we demonstrate the utility of ctDNA testing for MRD detection. Future prospective studies in RCC would be needed to validate the utility of ctDNA in informing clinical decision making.